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Abstract
Background: Genomics enables individualized diagnosis and treatment, but large challenges remain to functionally
interpret rare variants. To date, only one causative variant has been described for KCNK9 imprinting syndrome (KIS).
The genotypic and phenotypic spectrum of KIS has yet to be described and the precise mechanism of disease fully
understood.
Methods: This study discovers mechanisms underlying KCNK9 imprinting syndrome (KIS) by describing 15 novel
KCNK9 alterations from 47 KIS-affected individuals. We use clinical genetics and computer-assisted facial phenotyping
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to describe the phenotypic spectrum of KIS. We then interrogate the functional effects of the variants in the encoded
TASK3 channel using sequence-based analysis, 3D molecular mechanic and dynamic protein modeling, and in vitro
electrophysiological and functional methodologies.
Results: We describe the broader genetic and phenotypic variability for KIS in a cohort of individuals identifying an
additional mutational hotspot at p.Arg131 and demonstrating the common features of this neurodevelopmental dis‑
order to include motor and speech delay, intellectual disability, early feeding difficulties, muscular hypotonia, behav‑
ioral abnormalities, and dysmorphic features. The computational protein modeling and in vitro electrophysiological
studies discover variability of the impact of KCNK9 variants on TASK3 channel function identifying variants causing
gain and others causing loss of conductance. The most consistent functional impact of KCNK9 genetic variants, how‑
ever, was altered channel regulation.
Conclusions: This study extends our understanding of KIS mechanisms demonstrating its complex etiology includ‑
ing gain and loss of channel function and consistent loss of channel regulation. These data are rapidly applicable to
diagnostic strategies, as KIS is not identifiable from clinical features alone and thus should be molecularly diagnosed.
Furthermore, our data suggests unique therapeutic strategies may be needed to address the specific functional con‑
sequences of KCNK9 variation on channel function and regulation.
Keywords: KCNK9 imprinting syndrome, TASK3 channel, Neurodevelopmental disorder, Electrophysiology,
Computational protein modeling

Background
The field of clinical genomics is facing a challenge to
the paradigm that single genetic variants define specific
human diseases, or if a spectrum of genetic changes can
produce the same disease, or even be therapeutically
treated in the same way. Elucidating the precise mechanism of disease, especially for channelopathies where
agonists or antagonists may be clinically available, may
suggest specific pharmacotherapeutic interventional
opportunities. KCNK9 (MIM: 605874, NM_001282534.1)
encodes the TASK3 (TWIK-related acid-sensitive K
channel 3, K
 2P9.1) protein, a member of the two-pore
domain potassium (K2P) channel family [1, 2]. KCNK9
is among a small number of paternally imprinted genes
where only the maternal allele is expressed [3]. Recent
mouse studies, however, have detected residual paternal
expression in some brain regions [4]. KCNK9 imprinting syndrome (KIS), also known as Birk-Barel syndrome
(MIM: 612292), is a rare genetic disorder caused by a
genetic alteration of the maternal copy of KCNK9, first
reported with the causal variant, p.(Gly236Arg) [5], and
two subsequent variants of uncertain significance (VUS)
[6, 7]. KIS is characterized by pathophysiological symptoms, of variable severity, including dysmorphic features
with elongated face, varying degrees of intellectual
disability (ID), and congenital hypotonia [5, 8].
K2P channels participate in the stabilization of the resting membrane potential of excitable and non-excitable
cells, regulating cell activity. KCNK9-encoded TASK3
channels are predominantly expressed in the central
nervous system (CNS) where they contribute to background current in many neuronal populations [9, 10].
TASK3 knockout mice show a number of cognitive

impairments, and these channels are proposed to play a
role in various pathologic conditions including epilepsy,
pain and disorders of aldosterone secretion, respiratory
stimulation, and sleep duration [9]. Highly regulated by
physiological mediators, these channels are particularly
sensitive to increased extracellular acidification, resulting in channel inhibition [1, 9]. These channels are also
potently inhibited by activated G-protein-coupled receptors (GPCRs) that couple primarily through the Gαq protein family [11–13].
Because of the importance of this channel to human
pathophysiology,
several
laboratories,
including
ours, have devoted efforts to mechanistically
characterize its wild-type and variant-altered function.
Electrophysiological studies of the p.Gly236Arg variant
demonstrated reduced inwardly rectifying currents
which is insensitive to extracellular pH- and GPCRmediated regulation [14]. Transient expression of the
p.Gly236Arg variant in cortical pyramidal neurons
during development severely impaired migration, likely
contributing to developmental disorder in KIS [15].
Mice lacking TASK3 (Kcnk9-/-) have impaired memory
[16], sleep perturbation [17], and resistance to despair
behavior that has a link to depression [18]. Assuming a
loss-of-function mechanism, treatment strategies have
been proposed using channel-stimulatory drugs [8].
However, the precise mechanisms of KIS, and whether
additional variants cause the same disorder has remained
unknown.
The current study significantly advances the
knowledge of this syndrome by comprehensively
assessing 47 individuals with 19 unique KCNK9
variants. We characterize 15 novel variants using
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data modeling and cellular experiments to determine
how each alteration changes channel function and
interpret these data in the context of the clinical
findings. We found that KCNK9 variants can cause
gain or loss of channel function, and both exhibit the
pathognomonic characteristic of altered regulation.
Importantly, gain-of-function alleles thus may not be
amenable to channel-stimulatory drugs. Thus, this
study provides new knowledge of significant biomedical
relevance by advancing our current understanding of
this syndrome and its pathobiological mechanisms
while also demonstrating how computational and
experimental methods can be integrated to solve
disease mechanisms.

Methods
Participants

This study describes 47 affected individuals from 29
families. We describe 26 newly identified individuals
from 22 families (families F1-17, F23, F24, F26, F27, and
F29) accrued through professional communication as
well as through GeneMatcher [19]. They were recruited
from hospitals or clinics from the USA and other
countries including the UK, Germany, Italy, France,
The Netherlands, Canada, and Singapore. Clinical,
phenotypic, and KCNK9 genetic variant data were
analyzed for each participant. All families providing new
or updated data provided informed consent (F1-F19,
F23, F24, F26-F27, and F29). Data for families F20-F22,
F25 and F28 was abstracted from prior publications only.
This study was approved by the Mayo Clinic Institutional
Review Board, and local Ethics Committees. Family
9 was recruited to the Genomics England 100,000
Genomes Project. Previously published individuals with
KCNK9 variants are also described with summarized
published data and/or updated unpublished clinical
data [5–8]. Persons P18.1, P19.1, P20.1, and P21.1 in this
study refer to the published Patients 1-4 from Graham
et al. [8]. Family F22 refers to the Arab-Israeli kindred
described by both Barel et al. and Graham et al. [5, 8].
Person P25.1 refers to the individual reported by Šedivá
et al. [6], Family F27 was previously reported without
detailed clinical information [20], and person P28.1 refers
to BK-227-03 described by Guo et al. [7].
Variant identification

KCNK9 variants were identified through a variety
of methods including gene panel testing or exome
or genome sequencing through commercial clinical
laboratories including Ambry Genetics (Aliso Viejo,
CA), Baylor Genetics (Houston, TX), and GeneDx
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(Gaithersburg, MD), academic clinical laboratories,
or through research studies. Additional details are
provided in the individual clinical histories in the
Additional file 1: Supplementary Note.
Facial analysis

Face2Gene Research application (FDNA Inc., Boston,
MA) using DeepGestalt technology (algorithm 19.1.9)
[21] was used to evaluate the presence of a distinct facial
pattern in individuals with KCNK9 imprinting syndrome.
Seventeen frontal photos of the face were obtained
from unrelated affected individuals without glasses or
black eye bars (individual: age at photo: P3.1: 9y, P6.1:
10y3 m, P7.1: 9y, P8.1: 1y5 m, P9.1: 12y-18y, P12.1: 2y2 m;
P13.1: 6y1m, P16.1: 17y, P18.1 (updated photo patient
1) [8]: 6y, P23.1: 1y3 m, P24.1: 3 m, P27.1: 6y1m, P29.1:
8y1m and published photos of patient 2 (P19.1: 11 m), 3
(P20.1: 1y1m), and 4 (P21.1: 3y) from Graham et al. [8]
and the individual (P25.1: 17y) described by Šedivá et al.
[6] and compared to 17 control images matched for age,
sex, and ethnicity provided by Face2Gene. To estimate
the power of DeepGestalt in distinguishing affected
individuals from controls, a cross validation scheme was
used, including a series of binary comparisons between
all groups. For these binary comparisons, the data was
split randomly multiple times into training sets and test
sets. Each such set contained half of the samples from the
group, and this random process was repeated 10 times.
The results of the comparisons are reported using the
receiver operating characteristic (ROC) curve and area
under the curve (AUC). The mean AUC = 0.87 and AUC
STD = 0.07.
Molecular modeling

No experimentally solved structure currently exists for
the protein encoded by KCNK9, TASK3. Therefore, we
began molecular modeling from the canonical UniProt
sequence, Q9NPC2-1, which corresponds to Ensembl
transcript ENST00000303015 to search for existing
experimental structures of homologous sequences using
Clustal [22, 23] alignment to the Protein Data Bank
(PDB) [24]. Using I-tasser [25], we generated homologybased models for the highest homology experimental
structures - residues 1-271 from human KCNK1 (PDB:
3ukm) [26] and KCNK4 (PDB: 3um7) [27]. These
models were evaluated for quality using online servers
and standard metrics including PROCHECK [28],
QMEAN [29], QMEANBrane [30], and VADAR [31]. We
compared models to one another by calculations of their
electrostatic potentials, volumes, and accessible surface
areas using DaliLite [32] and APBS [33]. We summarized
quality metrics at the residue level to evaluate if
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differences in quality clustered in 3D. All structure
metrics were within expectation for high-confidence
membrane proteins. Regions that are embedded within
the membrane have high quality scores, comparable
to solvent-exposed loops on both intracellular and
extracellular-facing sides, which have lower quality
scores. We believe that these loops will be more flexible,
and therefore, any individual static representation of
them will be insufficient. Our use of replicates and
comparison to wildtype (WT) will help control for errors
in the initial placement of these loops and facilitate
interpreting the effects of genomic variants.
After completion of the 3D molecular modeling work
described above, an experimental structure for TASK1
(KCNK3) was released [34]. This protein is closer in
sequence identity to TASK3 (62%) compared to the
TWIK1 (KCNK1) and TRAAK (KCNK4) experimental
structures used as templates in this study (27% and
28%, respectively) [26, 27]. In our model, all amino
acids through Val243 are concordant with the TASK1
experimental structure. After Val243, our model
was disordered and highly dynamic in simulations,
concordant with the sequence not conforming to the
C-terminal of TWIK1 or TRAAK. In TASK1-based
models, Met249 faces into the membrane and we
computed Met249Thr to be destabilizing, consistent
in effect with our original analysis (see the “Results”
section). Thus, our modeling was highly concordant
with the TASK1-based model and we have interpreted
variants using information from both.
An explicit molecular environment was generated
using Visual Molecular Dynamics (VMD) [35] and
CHARMM-GUI [36, 37]. An 80x80Å membrane
bilayer patch of POPC was generated. The protein was
oriented to the patch using sequence-based annotation
of trans-membrane helices from UniProt and consensus
annotations from MESSA [38]. Water was added to
provide a 10 Å distance between TASK3 and environment
boundaries. The environment was neutralized at 150 mM
KCl by adding 75 K+ and 79 Cl− ions. This initial explicitenvironment system for WT TASK3 was used in further
modeling, as described below.
Structure‑based calculations

We scored genomic variants by 3D structure-based
algorithms. First, we generated dimer models of each
genomic variant using FoldX [39, 40] version 4 for
computational mutagenesis and calculating folding
stability changes upon mutation (ΔΔGfold). The explicitenvironment WT TASK3 system was modified for each
genomic variant using the FoldX-generated models. We
also assessed the initial models using Frustratometer
[41], to quantify how each genomic variant changes local
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interactions, from a more integrated perspective that
accounts for the many concurrent types of favorable and
un-favorable interactions of the mutated residues.
Molecular dynamics simulations

We studied the dynamics of KCNK9 genetic variants on
TASK3, and how they affect ionic interactions, using
molecular dynamics (MD) simulation as implemented
in the NAMD [42] software and the CHARMM27 force
field [43]. Each protein model was analyzed in triplicate,
beginning with energy minimization for 10,000 steps.
Next, harmonic constraints were added to protein nonhydrogen atoms and the system was heated to 300 K over
300 ps using a Langevin thermostat. Protein constraints
were gradually released over 1 ns. The entire system
was simulated free of restraints for a further 32 ns. In
total, we generated 110 ns of MD trajectory per variant.
Across variants and replicates, we generated 2.3 μs of MD
trajectory to study the effects of the variants in TASK3.
Molecular dynamics analysis

We calculated root mean-squared deviation (RMSD)
and root mean-squared fluctuation (RMSF) values using
Cα atoms after structurally aligning each trajectory to
the initial WT conformation and ignoring the mobile
C-terminus. We used principal component analysis
(PCA) to summarize the dominant conformational
changes across trajectories. PCs were calculated in
Cartesian coordinates using C
 α atoms. We calculated the
radial distribution function (RDF) for ions using VMD.
The RDF of K+ describes the normalized probability of
observing K+ ions within concentric shells. Electrostatic
surfaces were sampled over time by extracting periodic
frames from each simulation and assessed them each
using APBS [33, 44]. Analyses were carried out using
a custom structural bioinformatics workflow and
leveraging the bio3d R package [45]. Protein structures
and trajectories were visualized using PyMOL [45,
46] and VMD [35]. We generated our time-dependent
prediction of effect for each genomic variant using
a manual synthesis across multiple structure- and
dynamics-based metrics as well as manual inspection of
the simulation trajectories.
Mammalian expression plasmids

Human TASK3 
(GenbankTM AF212829) cDNA, was
cloned into the pcDNA3.1+ vector (Invitrogen, Carlsbad,
CA, USA), gifted by Helen Meadows (GlaxoSmithKline,
Harlow, UK) or into the pAcGFP1-N1 fluorescent vector
(Clontech-Takara Bio Europe). Plasmids encoding
for the human M3 muscarinic acetylcholine receptor
(GenbankTM AF498917) cDNA were obtained from the
UMR cDNA Resource Center (Rollo, MO).
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Mutagenesis

Each of the clinically identified KCNK9 variants (Arg131Ser, Arg131His, Arg131Pro, Met132Arg, Phe135del,
Met156Val, Met159Ile, Phe164Cys, Thr199Ala, Tyr205Cys, Gly236Arg, Ala237Asp, Met249Thr, Ala320Thr)
were introduced by site-directed mutagenesis into human
TASK3 cDNA using the QuikChange kit (Agilent, CA,
USA) as previously described [14]. Oligonucleotide primers were
synthesized by Eurofins MWG Operon, Ebersberg, Germany, and all constructs sequenced by DNA Sequencing
& Services, MRC/PPU, University of Dundee, Scotland.
Cell culture

All experiments were performed using a modified
human embryonic kidney 293 cell line, tsA201 (European
Collection of Authenticated Cell Cultures; SigmaAldrich, UK), prepared and maintained as previously
described [14]. Once cells reached 80% confluency, they
were split and resuspended in media at a density of
7 × 104 and 0.5 mL transferred to a 4-well plate containing
a poly-D-lysine-coated coverslip, ready for transfection
the following day.
Transfection

Plasmids containing cDNA for either WT or a mutated
TASK3 variant and a similar plasmid encoding the cDNA
for green fluorescent protein (GFP) were co-transfected
at a concentration of 0.5 μg using a modified calciumphosphate protocol, as previously described [14]. The
cells were then incubated at 37 °C in 95% O2 and 5% CO2
for 4–6 h, before being washed with phosphate-buffered
saline. The cells were used for experiments 18–24 h later.
All variants were expressed as homodimeric channels
(each α-subunit of the dimer expresses the incorporated
mutation) for all experiments. For experiments
measuring the effect of G-protein coupled receptors,
M3 receptors were also included in the transfection at a
concentration of 0.5 μg.
Whole‑cell patch‑clamp electrophysiology

Currents were recorded from GFP-fluorescing tsA201
cells expressing the cDNA of interest using whole-cell
patch-clamp in a voltage clamp configuration and a
step-ramp voltage protocol as previously described [14]
using an extracellular solution composed of 145 mM
NaCl, 2.5 mM KCl, 3 mM MgCl2, 1 mM CaCl2 and 10 mM
HEPES (pH adjusted to 7.4) and an intracellular pipette
solution of 150 mM KCl, 3 mM MgCl2, 5 mM EGTA, and
10 mM HEPES (pH adjusted to 7.4). All experiments
were conducted at room temperature (20–25 °C), and
currents were recorded using an Axopatch 1D patch
clamp amplifier (Molecular Devices, Sunnyvale, CA),
filtered at 2 kHz, digitized at 5 kHz. Extracellular control
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solution and modulatory compounds were perfused at a
rate of 4–5 mL min−1.
Electrophysiology data analysis and statistics

Data analysis of whole-cell outward current and analysis
software was as previously described in Cunningham
et al. [47]. Current-voltage graphs were obtained from
the voltage ramp (− 120 mV to + 20 mV). Data were
expressed as the mean ± 95% confidence intervals (CI),
and n represents the number of individual cells recorded.
Statistical analyses used were either a one-way ANOVA
with a post-hoc Dunnett’s multiple comparisons test or
an unpaired/paired Student’s t-test. Data was considered
statistically different if P < 0.05 (*), P < 0.01 (**), P < 0.001
(***), and P < 0.0001 (****). Data from variants was
compared with matched control data from WT TASK3
recorded either simultaneously or around the same
calendar period and cell batch number.
Confocal microscopy

Colocalization studies were performed according to the
detailed methods outlined in Cunningham et al. [47]. In
brief, WT human TASK3 and human TASK3_Tyr205Cys
cDNA’s were subcloned into the pAcGFP1-N1 fluorescent
vector (Clontech-Takara Bio Europe) to create a fusion
construct with GFP and expressed in tsA201 cells using
TurboFect transfection reagent (ThermoFisher, Loughborough, UK). Prior to fixing the cells, the plasma
membranes of the cells were stained with CellMask
Deep Red (CMR) (ThermoFisher, UK) and the nuclei
with Hoechst 33528 (Sigma-Aldrich, UK). Coverslips of
cells were mounted with Vectashield anti-fade mounting
medium (Vector Laboratories, UK).
Confocal microscopy images were taken using a LSM
880 confocal microscope (Carl Zeiss, Oberkochen, Germany) and processed using Zen Black software (Carl
Zeiss). Cells were excited with an argon laser at either
561, 488, or 405 nm for the CMR plasma membrane
stain, pAcGFP fused channel and Hoechst 33528 stained
nuclei, respectively.
Colocalization was determined using Zen Black
software and Pearson’s correlation coefficient (PCC) was
used to represent the degree of co-localization.
Chemicals

Muscarine chloride, zinc chloride, dithiothreitol, 5-dithiobis(2-nitrobenzoic acid), and methanethiosulfonates
were all purchased from Sigma-Aldrich, UK. For high
potassium (25 mM K) or acidic pH (pH 6.4) experimentation, the extracellular solution was adjusted
accordingly. Muscarine chloride was added directly to
extracellular solution at a concentration of 0.1 μM prior
to use.
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Functional study correlation and variant pathogenicity
classification

To appropriately weight the strength of functional
evidence provided by computational modeling and
in vitro electrophysiological studies, we generated a
weighting scheme for each. For computational modeling,
we primarily used four dynamic features as follows (see
Additional file 2: Table S1): The “Δ3-HB bbn RMSD”
is the change in protein backbone RMSD among the
3-helix bundles. Since the WT channel exhibits dynamics
in simulations (median of 2.8 Å RMSD), we binned this
metric into three levels based on how distorted the 3HBs
were for each variant compared to WT: ≥ 0.3 ΔRMSD,
within 0.3 ΔRMSD, and ≤ − 0.3 ΔRMSD compared to
WT simulations. The “SSR of Filter C
 α RMSF” is the sum
of squared residuals for the selectivity filter alpha-carbon
RMSF, between WT and each variant. We binned this
metric into three levels compared to WT: greater than
1.0, between 1.0 and 0.5, and less than 0.5. The selectivity
filter depends not only on the backbone, but also on
sidechain orientations. So, we quantified the “Δside chain
heavy atom RMSD TIG (Thr-Ile-Gly) motifs” binned into
greater than 0.5, within 0.5, and less than 0.0. Finally, we
used “anti-chamber open/close by PCs” to indicate if a
single PC feature indicated opening the antechamber,
two PC features indicated opening, no change, a single
feature of more closed antechamber, and two features of
more closed antechamber (Additional file 3: Video S1).
For the electrophysiological studies, we used a two-step
approach applying more weight to current than the other
measured channel attributes. We first weighted each assay
result: current amplitude (0–3 corresponding to the level
of statistical significance (0: not significant; 1: 0.001 < P
< 0.01; 2: 0.0001 < P < 0.001; 3: P < 0.0001) and regulation by
GPCR or by pH (0: not significant; 1: P < 0.05) and added
weights for each variant (max weight = 5). These were
then rescaled to a 0–3 scale (0: sum weight = 0; 1: sum
weight = 1; 2: sum weight = 2–3; 3: sum weight > 3). The
only exception to this was the Tyr205Cys variant which
had no measurable current but would have only received
a sum weight of 3 since regulation by GPCR and pH could
not be measured without any baseline current, but the
damaging evidence was more significant than that weight
alone.
Variants were classified according to the 2015
Guidelines by the American College of Medical Genetics
and Genomics and Association for Molecular Pathology
guidelines [48]. Per current ClinGen guidelines,
PM2 was used as a supporting level of evidence
[49]. Conservatively, PS2 was applied as a moderate
level of evidence due to KCNK9 being a paternally
imprinted locus. PP3 was determined using CADD
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[50], MutationTaster [51], PrimateAI [52], SIFT [53],
and Polyphen2 [54] (dbNSFP version 4.1 [55]) applying
supporting level of evidence when 3 or more tools predict
a damaging impact (Additional file 2: Table S1). The
weight for functional evidence (PS3) was applied using
only the electrophysiological data by the rescaled weight
(none = 0; supporting = 1; moderate = 2; strong = 3).
Agreement between computational and in vitro impact
of variants was assessed using Spearman correlation and
linear regression models.

Results
Diverse genomic variation in KCNK9

This study describes 47 affected individuals with heterozygous KCNK9 variants from 29 families. We summarize the originally described Arab-Israeli kindred of
15 affected individuals and six previously published singletons in addition to the 26 newly identified individuals
from 22 families harboring 15 unique, novel KCNK9 variants (Fig. 1A).
KCNK9 is paternally imprinted, allowing pathogenic
variants to be present on the paternal allele without causing disease, and thus could be found in healthy populations. We observed that KCNK9 is nearly intolerant to
missense variation with a gnomAD (v2.1.1) [56] missense
constraint Z-score = 2.9 (observed/expected ratio = 0.48;
CI 0.41–0.56) where significant constraint is Z > 3.09.
KCNK9 is less constrained than other genes causing
dominant neurodevelopmental disorders [57], however,
and 9/19 variants (Additional file 2: Table S1) fall in constrained coding regions (CCR) > 95th percentile [58]. The
identified KCNK9 variants (Fig. 1A, B and Additional
file 2: Table S1) are absent or extremely rare in the population and fall either within the transmembrane (TM)
or the intracytoplasmic domains, without occurring in
the extracellular regions of the protein, and most affect
highly conserved residues (Fig. 1C). Six families carry the
p.(Gly236Arg) variant affecting 20 individuals, a known
alteration hotspot. Among the novel variation identified
in our cohort, eight families with nine affected individuals
carry missense alterations at Arg131, including five families with p.(Arg131His), and one each with p.(Arg131Cys),
p.(Arg131Pro), and p.(Arg131Ser) in an affected sibling pair. Two siblings from an additional family have
the neighboring residue modified by a p.(Met132Arg)
variant. Additionally, two unrelated probands have a
p.(Met159Ile) variant. The remaining variants identified
were unique to each family. Congruent with KCNK9
paternal imprinting, ten families demonstrated maternal inheritance and in 16 families the variant occurred
de novo in the affected individual or the mother
(Additional file 2: Table S1). Thus, we have identified
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Fig. 1 Individuals with KCNK9 imprinting syndrome. A KCNK9 coding exons showing all variants by predicted protein change using ProteinPaint
(St. Jude Children’s Research Hospital). The number in the circle represents the number of families described with the variant, no number = 1 family.
Previously published variants are gray. B TASK3 protein topology schematic showing the location of variants. C Conservation of residues affected
by variants. Bars in top line indicate variant position. D Front and profile photos of individuals with KCNK9 variants. The age at time of photograph
is: P2.1: 1y 6 m, P3.1: 9y, P6.1: 10y 3 m, P7.1: 9y, P8.1: 1y 5 m, P9.1: 12y-18y, P9.2: 12y-18y, P12.1: 2y 2 m; P13.1: 6y 1 m, P15.1: 58y, P16.1: 17y, P18.1
(updated photo, Pt. 1, Graham et al. 2016): 6y, P23.1: 1y 3 m, P24.1: left 3 m, right 5y, P27.1: 6y 1 m, P27.2: 8y1m, P27.3: 28y, P29.1: 8y 1 m. y = years;
m = months. E Facial analysis using Face2Gene Research application (FDNA Inc. Boston, MA) of individuals with KCNK9 imprinting syndrome (frontal
photos of P3.1, P6.1, P7.1, P8.1, P9.1, P12.1, P13.1, P16.1, P18.1, P19.1*, P20.1*, P21.1*, 23.1, P24.1 (3 m photo), 25.1*, 27.1, and 29.1 compared to age,
sex, and ethnicity matched controls. The aggregated binary comparison (AUC = area under the curve, ROC = receiver operating characteristic)
demonstrates a significant difference between the two cohorts (P < 0.05). *used published photos

diverse genetic alteration of TASK3 channels associated
with KIS that lacked mechanistic understanding and disease association, motivating the functional characterization of them.

Spectrum and variability of clinical phenotypes associated
with KCNK9 variation

By assessing the available clinical data, we describe the
phenotypic spectrum and variability across our cohort
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(Table 1). Detailed clinical histories are provided in the
Additional file 1: Supplementary Note. Most individuals
presented with neurodevelopmental delays, ID, hypotonia,
behavioral abnormalities, and facial dysmorphism.
Neurologically, the majority of individuals were affected
with mild to severe profound ID (n = 24 families, 83%)
and motor (n = 26, 90%) and speech (n = 27, 93%) delays
with mild to profound muscular hypotonia (n = 25, 86%)
especially during infancy. This was often accompanied
by myopathic changes on muscle biopsy and electromyography (EMG). Behavioral and cognitive abnormalities
were common (n = 17, 59%) and included attention deficit
hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and aggressive, impulsive, or violent behavior.
For example, proband P6.1 displayed autistic features with
stereotypies (Additional file 4: Video S2).
Afebrile seizures were reported in five families (17% of
families, Additional file 5: Table S2). Five of 15 affected
individuals from family F22 reportedly developed seizures, but without further detail [5, 8]. The four additional
probands (P11.1, P12.1, P13.1, and P18.1) who reported
afebrile seizures had seizure onset between 2 and 8 years
of age. Seizures were well controlled with medication
(single or combination therapy including lamotrigine,
sodium valproate, clonazepam, or oxcarbazepine). In
three of these individuals, febrile seizures and unconfirmed episodes concerning for seizures preceded afebrile
seizures with onset as early as 1 month of age. Three additional individuals (P3.1, P4.1, and P29.1) reported febrile
seizures only and P1.2 experienced episodes of suspected
absence seizures that were not confirmed.
Dysmorphic features were reported in all individuals with data available (Table 1 and Fig. 1D). Analysis of
facial photos (Fig. 1E) of 17 unrelated individuals with
KIS compared to matched controls using unbiased facial
recognition software [21] demonstrated a statistically significant difference in dysmorphic facial features across
our cohort (P = 0.014, AUC = 0.88 ± 0.05). The composite
facial gestalt image demonstrates elongated face, arched
eyebrows, downturned corners of the mouth, thin upper
lip, tented upper lip, short philtrum, and bitemporal
narrowing. Additional features including thick alveolar ridges, cleft or high palate, and tapered fingers were
relatively common. Thus, these descriptions extend and
refine the spectrum of signs and symptoms that characterize this syndrome.
TASK3 variants display altered molecular mechanics
and dynamics properties

We used models of 3D TASK3 channels (Fig. 2A–C),
leveraging experimental data from the gene family, in
calculations of a variant’s effect on the protein (N = 14;
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Table 2). Protein structural modeling in 3D enables calculations of specific biochemical and biophysical details.
Such calculations provide information that is distinct
from genomics algorithms [59] and enable us to evaluate variant impact on channel mechanics. Using the 3D
models, we simulated TASK3 dynamics (Additional
file 6: Fig. S1), which were consistent across technical
replicates (not shown) and revealed mutation-specific
mechanics (Fig. 2D-G; details in Additional file 1: Supplementary Note). Gly236Arg indeed occluded, placed
positive charge within the channel antechamber (Fig. 2D)
and distorted the selectivity filter (Additional file 6: Fig.
S2A). The selectivity filter is characterized by a ring of
hydrophobic and aromatic residues that form interactions between monomers and facilitate transport through
the channel (Additional file 6: Fig. S2B). Simulations
also showed rearrangements of the selectivity filter for
Arg131His, while Met132Arg led to blockage of mutated
channels and Phe135del distorted both regions, supporting an interpretation of reduced function (Additional
file 2: Table S1). The remaining mutated channels, other
than Phe164Cys and Ala237Asp, showed a more open
channel interior in simulations (Table 2), which we interpreted as being more permissive to ion transport. Some
variants simultaneously showed features that could associate with being less permissive, such as Arg131His which
had a distorted selectivity filter, and Arg131Ser which
had a narrower channel entrance. To better summarize
aggregate effects across these protein dynamics changes,
we quantified changes to K+ distribution at key locations (Additional file 6: Fig. S3 and S4) and found severe
depletion of K+ nearby the selectivity filter for Gly236Arg
(Fig. 3A). At the cytoplasmic face, Gly236Arg showed
nearly no K
 +, Arg131His showed little, and Met159Ile
comparatively more but still diminished compared to
WT (Fig. 3B). Simulations even demonstrated the partial
rescue of Gly236Arg by Ala237Thr co-mutation, previously shown experimentally [14] (Fig. 3C and Additional
file 1: Supplementary Note), supporting the mechanistic
value of the data. Interestingly, [ K+] around the selectivity
filter and ΔΔGfold were significantly correlated (ρ = 0.50),
indicating a link between our structure- and dynamicsbased calculations. Together, blinded to the electrophysiology data (below), simulations predicted loss of function
for Gly236Arg, Phe135del, and Met132Arg, little change
for Phe164Cys and Ala237Asp, likely gain of function,
but with a mix of gain- and loss-associated features, for
Met156Val, Arg131His, Arg131Ser, and gain of function
for Arg131Pro, Met159Ile, Thr199Ala, and Met249Thr
(Table 2). Thus, 3D structural and time-dynamic simulations enriched the information available from genomics,
for explaining mutated TASK3 channel mechanics.
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Table 1 Phenotypes of individuals with KCNK9 variation
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Fig. 2 TASK3 structure and variant locations. A We modeled TASK3 in an explicit environment and show the dimer colored by monomer. We omit
the environment from other images for simplicity. B We mark the locations of variants observed in our cohort. Pink spheres mark sites of variants
in one monomer and cyan sphere in the other. R303C and A320T fall outside of the modelable region. C We show the same view of TASK3, colored
by features of the structure that we will use in describing the effects of genomic variants. We colored only one monomer since features overlap.
The trans-membrane (TM) helices form the core of the structure and three of them form a type of 3-helix bundle (3-HB). TIG motifs form the lower
section of the selectivity filter and are colored black. The C-terminus is predicted to fold along the intracellular-facing side and may participate in a
gating mechanism. Most variants are on the intracellular-facing side or facing into the interior central chamber, indicated by an i. D G236R places
positively charged Arginine side chains facing inside of the channel, not only occluding it but likely adding a cation blockade. E From our MD
simulations, we also observed consistent conformational changes associated with G236R. F The variant M159I, which occurs within the 3-HBs, was
also associated with a consistent change in N-terminal helix orientation. G Three different variants of R131 are observed and have effects on 3-HB
organization and orientation relative to the N-terminal helix

Electrophysiological studies reveal altered current
by TASK3 variants

To evaluate the functional impact of KCNK9 variants
on TASK3 channel properties, we performed whole-cell
patch clamp electrophysiology to record currents passing
through 15 clinically identified KCNK9 channel variants,
transiently expressed in human tsA201 cells and characterize their properties, (Additional file 7: Table S3). The
KIS variant, Gly236Arg, introduces a positively charged
arginine in the TM4 region of the channel and gives
significantly reduced (P < 0.05) and inwardly rectifying
currents [14]. For 13 novel variants (Arg131Ser, Arg131Cys, Arg131His, Arg131Pro, Met132Arg, Phe135del,
Met156Val, Met159Ile, p.Phe164Cys, Thr199Ala,
p.Ala237Asp, Met249Thr, p.Ala320Thr), however, the
opposite effect—outwardly rectifying pico-ampere (pA)
currents—was observed, determined by ramp changes

in holding potential from − 120 to + 20 mV (Fig. 4A–C
and Additional file 7: Table S3). Seven of these variants (Arg131Ser, Arg131Cys, Arg131His, Arg131Pro,
Met159Ile, Thr199Ala, Met249Thr) had significantly
increased outward currents (P < 0.05, unpaired t-test),
while Met132Arg and Phe135del, located on the intracellular cytoplasmic loop between TM2 and TM3, had
significantly (P < 0.05) reduced outward currents (Fig. 4A
and Additional file 7: Table S3), compared to experimentally matched WT controls. Interestingly, the remaining
four variants (Met156Val, Phe164Cys, Ala237Asp, Ala320Thr) were functionally indistinguishable from WT
in this assay (Fig. 4A). Twelve variants had mean zero
current potentials similar to WT (P > 0.05) and close to
the equilibrium potential for K
 + under these recording
conditions (Fig. 4A–C). The Phe135del variant was the
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Table 2 KCNK9 variants in this study assessed for TASK3 structure- and dynamics-based changes
Protein variant ΔΔGfold
R131S
R131H
R131P
M132R

1.36 ± 0.17

1.05 ± 0.17

6.87 ± 0.65

− 2.63

− 1.48

4.34

1.13

PC2 (2.6σ)

8

1.26

n.s.

4

− 0.71 PC2 (− 1.1σ)
PC3 (1.5σ)

10

--

0.39

–––

Occluded-permissive

1.42

–

Mixed-permissive

1.08

––

Mono-permissive

14

n.s

2.30

NA

NA

PC3 (− 2.4σ)

9

n.s

1.52

–

Mixed-permissive

M156V

2.54 ± 0.17

− 3.75

1.22

n.s.

6

0.62

–––

Permissive

0.86

n.s.

+

T199A
Y205C

8.01 ± 0.52

3.48 ± 0.43

− 22.18

− 31.18

0.92 ± 0.14

1.83

4.01 ± 0.63

− 5.57

− 1.21 PC3 (− 1.1σ)

+

+

NA

M159I

14.77

Transport ΔElec surface Selectivity Δ[K+] c Blinded prediction d
events b
Filter [K+] c

F135del

F164C

2.74 ± 0.10

ΔFour-body Pot. ΔSRLF ΔPC a

− 0.55 PC1 (1.2σ)

0.08

PC2 (− 2.7σ)
PC3 (2.3 )

2.94

n.d.

8

+

Mixed-permissive

1.93

n.s

Permissive

8

n.s

2.92

Permissive

12

+

1.93

++

+

n.s

Permissive

n.d.

n.d.

n.d.

n.d.

n.d.

G236R

− 2.59 ± 0.54 − 3.41

− 0.46 PC2 (− 2.8σ)
PC3 (1.6σ)

0

++

0.25

–––

Occluded

G236R & A237T

− 2.40 ± 0.54 0.32

NA

10

++

0.81

––

Occluded-attenuated

A237D
A237T
M249T

5.36 ± 0.17

0.13 ± 0.07

6.41 ± 0.83

13.51
− 0.60

5.09

PC1 (− 2.0σ)
PC3 (− 2.4σ)

− 1.85 PC2 (− 1.3σ)

− 0.76 PC2 (− 2.9σ)

0.59

PC2 (− 3.1σ)
PC3 (1.2σ)

8

n.s

1.37

–

Permissive

4

+

1.80

n.s

Moderately permissive

2.00

n.s

Permissive

1

--

SRLF single residue level frustration, NA not applicable, n.d. not determined
a

PC alterations of at least 1 standard deviation (σ) away from WT are noted; others are labeled as not significant (n.s.); data used ignored the C-terminus (see
Methods)

b

Compared to a WT value of 2 transport events

c

Defined based on the K
 + radial distribution functions (Fig. S4 and S5) at 6.9 Å from residues 94 and 200. Comparisons are to the WT value of 1.8

d

Using only the computational simulation data, we predict if the variants will impair potassium transport or not

only variant that displayed a significant (P < 0.05) shift
in reversal potential to become more depolarized, similar to that observed with Gly236Arg. Tyr205Cys occurs
in the second pore (P2) region of the channel and was
non-functional under our experimental conditions,
with no measurable current and zero current potentials
(Additional file 7: Table S3), indistinguishable from green
fluorescent protein (GFP)-only transfected cells. Using
fluorescently tagged channels in confocal microscopy
of WT, Gly236Arg, and Tyr205Cys channels, we found
that Tyr205Cys channels had similar TASK3 protein
levels at the plasma membrane as WT channels (Additional file 6: Fig. S5), suggesting the Tyr205Cys variant is
trafficked as efficiently to the plasma membrane as WT.
Attempts to restore current through Tyr205Cys channels
using cysteine-modifying agents (dithiothreitol (DTT),
5″-dithio-bis(2-nitrobenzoic acid) (DTNB or Ellman’s), or
methanethiosulfonates (MTS)) were unsuccessful (Additional file 6: Fig. S6). Thus, the novel variation studied
was dissimilar to Gly236Arg and significantly different in
current density from WT, supporting its role in defining
KIS but with a distinct underlying mechanism.

Alterations in TASK3 regulation is a dysfunctional feature
shared by KIS variants

Sensitivity to extracellular pH changes is a hallmark regulatory fingerprint for TASK3 channels. With a pKa of 6.7,
TASK3 channels are inhibited by increased extracellular
acidification from physiological pH [1, 60, 61]. Interestingly, Gly236Arg mutated channels demonstrate reduced
sensitivity to extracellular acidification (Additional file 8:
Table S4 and see Veale et al. [14]). By determining the pH
sensitivity of the novel TASK3 variants, we find that ten
of the 13 variants had decreased sensitivity to extracellular acidification from pH 7.4 to 6.4 (Fig. 4A, D and Additional file 8: Table S4) similar to Gly236Arg channels;
we found no change in pH sensitively with Met156Val,
Met249Thr, or Ala320Thr. Tyr205Cys could not be measured due to a lack of measurable current at − 40 mV.
These data show that most variants are associated with a
similar disruption of channel regulation by extracellular
acidification as the Gly236Arg channels.
Notably, TASK3 channels are also regulated by activated GPCRs leading to inhibition, and Gly236Arg
channels show complete loss of 
Gαq-mediated channel inhibition (Additional file 9: Table S5, and see Veale
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Fig. 3 Functional alterations in TASK3 are associated with altered ion distribution. We show, here, selected examples with broader characterization
in Additional File 6: Fig. S6 and S7. A We show smoothed K+ RDF for selected variants, with M159I and R131H showing WT-like but lower presence
of K+ around the selectivity filter and a depletion for G236R. B The smoothed K + RDF centered at residue 236, which is towards the cytoplasmic
face, again shows a drastic depletion for G236R, less drastic for R131H, and a more modest change for M159I. C Smoothed K + RDF centered around
the selectivity filter shows that the significant depletion for G236R is partially rescued by the A237T double-variant with a modest increase for A237T
alone. This is consistent with previously reported experimental assays that showed A237T to be a partial compensating variant for G236R

et al., 2007, 2014) [13, 14]. Thus, we assayed the loss of
 αq-mediated channel inhibition in the presence of
G
0.1 μM muscarine and found that seven of the 13 channels (Arg131Ser, Arg131Cys, Arg131His, Arg131Pro,
Phe135del, Met159Ile, Ala237Asp) exhibited significantly
(P < 0.05) reduced G
 αq-mediated inhibition (Fig. 4A, E
and Additional file 9: Table S5) similar to Gly236Arg,
whereas Ala320Thr exhibited increased sensitivity
to Gαq-mediated inhibition. The five remaining variants, (Met132Arg, Met156Val, Phe164Cys, Thr199Ala,
Met249Thr), retained a sensitivity to G
 αq-mediated inhibition similar to WT controls (Fig. 4A). These studies
show that activated GPCR regulation of TASK3 channels is altered by a majority of clinical variants, similar
to Gly236Arg, and suggest channel regulation as a defining functional consequence of clinical KCNK9 variation
associated with KIS.
Integrated computational and experimental assessment
of altered channel mechanisms

We assessed the congruency of the computational
and experimental results and show the computational
assessment, blinded to in vitro data, was concordant
with in vitro data. We categorized the in vitro and computations evidence, each, into the following weights
of impact (Additional file 2: Table S1; see methods
for details): none (no change from WT; weight = 0),

supporting (differences are observed, but clinical significance is unclear; 1), moderate (function is likely
impaired; 2), and strong (function is altered consistent
with being disease causal; 3). All variants computationally predicted to occlude the channel were of strong
impact, experimentally. Three of the four variants with
computationally modeled features showing the channel being both more- and less-permissive were of strong
impact (the fourth was of moderate impact), experimentally. Of the remaining six variants, four were of
moderate impact and one each of supportive and strong
impact, experimentally; among these six, computations
were concordant with in vitro impact class but predicted a greater impact for Met156Val and Ala237Asp
and a lesser impact for Met159Ile and Ala320Thr. Met156Val is unique among the in vitro tests for no measured impact on intrinsic function or regulation. A
further three, Phe164Cys, Ala237Asp, and Ala320Thr,
have minimal-to-no change in intrinsic protein function but do alter how it is regulated. Importantly, our
computational models were not setup to test changes
in channel regulation. Finally, Met159Ile has among the
most damaging structure-based scores (Table 2). Thus,
while we see fewer deformations of the Met159Ile channel in simulations, Met159Ile is predicted to alter the
structure of TASK3. Therefore, the biochemical and
mechanical link between our simulations and in vitro
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Fig. 4 Effect of individual protein changes on channel regulation by various modulators. A Boxes highlighted blue denote an increase in the
measured parameter compared with matched WT controls where ↑P < 0.05, ↑↑P < 0.01, and ↑↑↑P < 0.001, and ↑↑↑↑P < 0.0001, determined using
an unpaired Student’s t-test. Boxes highlighted gray denote a decrease in the measured parameter compared with WT, where ↓ P < 0.05, ↓↓P < 0.01,
↓↓↓P < 0.001, and ↓↓↓↓P < 0.0001. White boxes signify no change in effect from WT (←→P ≥ 0.05). Green boxes signify non-functional variants
and mirror GFP-only transfected cells. B Current amplitude vs time. C Current amplitude vs Voltage. D Inhibition by acidic pH. E Inhibition by
muscarine. ***P < 0.001 and ****P < 0.0001 for between group differences, determined using an unpaired Student’s t-test. Square or circle symbols
represent individual data points for each condition and channel. Error bars represent 95% confidence intervals. pA, picoamp; pF, picofarad; VREV,
reversal potential; ms, millisecond; mV, millivolt; M3, muscarinic receptor 3

data indicates their mutual value for interpreting the
effects of genetic variants.
Then, we further datamined our simulations for which
features associated best with experimental results. We
found that alterations of position for the TIG motif that
defines the selectivity filter and 3-Helix Bundle (3-HB)
organization appear to be the most consistent structural
features that associate with current amplitude changes
(Additional file 2: Table S1). Four variants (Met132Arg,
Phe135del, Gly236Arg, and Tyr205Cys) demonstrated
decreased or no current amplitude experimentally. By
computations, these four all showed greater distortion
of 3-HB, compared to WT. Concurrently, Met132Arg
and Phe135del had a more closed antechamber and
Gly236Arg a more open antechamber. Thus, these four
variants are predicted to be more conformationally
unstable, leading to loss of amplitude. Six variants (Arg131Ser, Arg131His, Arg131Pro, Met159Ile, Thr199Ala,
and Met249Thr) have increased amplitude by electrophysiology. All six except Arg131Ser had less distortion
of 3-HB. Concurrently, Arg131Pro and Met249Thr have
a more open antechamber, and Arg131His/Ser had a
more closed antechamber. TIG motifs are significantly
altered for all six except for Arg131Pro. Thus, these
variants were overall more conformationally stable, but

TIG alteration indicated a loss of conformational control over ion movement. Three variants (Met156Val,
Phe164Cys and Ala237Asp) demonstrated normal WT
current amplitudes in electrophysiological assays. These
three showed varied alteration of the 3-HBs and TIGs
in simulations. A large 3-HB alteration was calculated
for Ala237Asp, although no affect was seen on current
amplitude, unlike the gain-of-function Ala237Thr synthetic variant [14, 62]. Deviation of the TIGs was minor
for Phe164Cys and Met156Val but large for Ala237Asp.
These three variants have mixed 3D features that support an overall neutral to modest increase in amplitude, concordant with our experiments. Thus, structural
simulations and functional experiments provided inferences on how mutated TASK3 channels may become
dysfunctional.
Correlation of functional properties of KIS variants
and pathogenicity classifications

We next sought to classify the KCNK9 variants using
a 5-point pathogenicity scale from benign to pathogenic using all relevant and available data for each
variant. DNA-based predictive algorithms were nearly
unanimous in the variants being damaging, save
p.(Met156Val) and p.(Ala320Thr) (Fig. 5A). Our in vitro
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Fig. 5 Combining experimental and computational approaches adds mechanistic detail to interpreting genetic variants. A Most DNA
sequence-based algorithm predicts our cohort’s variants uniformly, but there is a stark lack of consensus among them. Each genomic score was
thresholded according to how we used them to the ACMG classification PP3 criteria. B Our experiments clarified specific functional changes for
each mutated protein, resulting in an in vivo impact class and C updating the ACMG classification of each variant. D Computational assays were
additionally summarized and demonstrated variant-specific changes to key regions of the protein and resulting in a predicted impact class (further
detail in Additional file 2: Table S1). E The impact classes from experimental and computational approaches were highly concordant, demonstrating
the potential for computational tools to enhance the information available for interpreting genetic variants. We summarized concordance using a
bubble plot with radius proportional to the number of variants in each class. Variants are colored according to their ACMG Class, and bubbles are
colored according to Impact Class (left side computational and right in vitro)

data was more nuanced and demonstrates that each variant can have unique features, but that channel regulation was most consistently disrupted (Fig. 5B). To gauge
the strength of evidence supporting a damaging interpretation for the in vitro heterologous cell-based studies, and for the computational modeling studies, we
used the four-point weights of impact calculated above
(Additional file 2: Table S1; see methods for details). To
classify the KCNK9 variants in terms of pathogenicity, we used the current American College of Medical
Genetics and Genomics and Association for Molecular Pathology guidelines [48] (Fig. 5C and Additional
file 2: Table S1). Therefore, concordant with these
guidelines, we considered only the in vitro cell-based
studies as contributory for PS3 and applied the most
weight to current amplitude (see methods for details).
Using existing data, four of the 19 KCNK9 variants

would be classified as pathogenic, seven as likely pathogenic, and eight remained VUS. The in vitro data we
gathered in this study promoted three VUS to likely
pathogenic and one likely pathogenic to pathogenic
(Fig. 5C). Computations also demonstrated nuanced
patterns, which we summarized above using distortion
of the 3-HBs and TIGs (Fig. 5D). The variants had a
very similar strength of evidence supporting a damaging impact on the protein from both experimental and
computational approaches (Fig. 5E; rank correlation
ρ = 0.72, P = 0.0041). Thus, the interpretation of our
data in terms of these guidelines provides information of immediate application to clinical medicine, yet
nuances from computational and in vitro experiments
indicate that information with more detailed mechanistic value can improve the interpretation if KIS
genetic variants.
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Discussion
The current study makes significant contribution to
the understanding of the field of channelopathies in
general and to KIS, in particular, by characterizing a
sizable cohort of individuals with novel genetic variants in KCNK9 affected with this neurodevelopmental
syndrome. In addition, we comprehensively characterize the functional impact of the variants using a multitiered approach. We report 26 previously unpublished
individuals with 15 novel variants displaying phenotypic traits similar to those with the previously reported
Gly236Arg variant associated with KIS. Moreover,
we report the existence of two mutational hotspots in
KCNK9, occurring at the previously reported Gly236
and the newly identified Arg131 codons. Computational protein modeling, molecular mechanic calculation, molecular dynamics simulations, and whole-cell
patch-clamp electrophysiological techniques, when
combined, strongly suggest that the large majority of
these variants alter channel function and herein we
classified them as pathogenic or likely pathogenic
for KIS.
Fortunately, assembling this large mutational landscape for KIS allowed us to perform detailed clinical
phenotyping of 47 affected individuals from 29 families
with this syndrome (Table 1). The predominant features
of this disorder include motor and speech delay, ID,
early feeding difficulties, muscular hypotonia, behavioral abnormalities including hyperactivity and aggression, and dysmorphic features including an elongated
face, permanent open mouth, microretrognathia, high
arched eyebrows, and bitemporal narrowing. Less
common features include seizures that can develop in
childhood and were mostly controlled by medications,
combined obstructive and central sleep apnea, and scoliosis. These features are consistent with the originally
described p.(Gly236Arg) variant, but with a wider range
of severity. Other syndromes that might be considered
in the differential diagnosis include 22q deletion syndrome, Cohen syndrome, and Prader-Willi syndrome.
The constellation of clinical features observed in KIS
is not specific enough to make this disorder easily recognizable in the clinic, and it will therefore require a
molecular diagnosis to confirm.
Unlike the original Gly236Arg mutant channels,
which have reduced inwardly rectifying current [14],
over 50% of the newly described variants had significantly increased outward currents. Notably, although the
novel KIS variants had variable effects on channel current, they had a much more consistent impact on TASK3
regulation by extracellular pH and also by activated
GPCRs. Taking into consideration general principles
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of protein dynamics, genetic variants can shift the balance of motions and thereby alter protein function [63,
64]. Variants that occur at sites within the lower 3-HB
(Arg131, Met132, Phe135, Met156, Met159, and Ala237)
likely alter hydrophobic packing of the region giving an
increased probability of K+ near the channel pore and
more K+ transport events. This is in stark contrast to the
decrease seen with Gly236Arg, suggesting distinct channel dysfunction by these novel variants. In particular,
genetic variants at position 131 lead to different extents
of distortion that pull the N-terminal helix inward while
also pulling the 3-HB helices outward. These changes
displace the C-terminus of the other monomer from its
normal interaction, and it shifts inwards into the ion
transport cavity. This shift is greatest for Arg131His
with Arg131Pro and Arg131Ser having more variability
between them. Thus, we believe distortion of the 3-HB
configuration could provide a novel metric for tracking
the disruption of the channel by genomic variants.
The Tyr205Cys variant occurring immediately after
the conserved ion selectivity filter sequence (GFG) in the
second pore region of the channel resulted in completely
non-functional channels. This loss of function is most
likely the consequence of replacing an amphipathic tyrosine with a hydrophobic cysteine residue in an aqueous
environment. Aromatic residues such as tryptophan and
tyrosine have been shown to be important in the pore
region of KcsA (K channel of streptomyces A) channels
in determining the final dimensions of the extracellular
mouth of the pore [65].
Ideally, the rate of conductance from simulations would
be directly relatable to experiments. While we observed
multiple ion transport events, there were more ion transport events than WT in most mutated channel simulations, indicating that the length of simulations used may
not be sufficient for direct computational measurement
of conductance. Future studies will extend our initial
work, such as determining the level of simulation details
and time required to directly match experimental conductance measurements.
Overall, both the directionality and magnitude of
changes seen through computational molecular structural assessment are largely concordant with the electrophysiological studies. This suggests that these
assessments are not only useful in clarifying the underlying molecular causes of the measured electrophysiological changes but may also be used alone to provide
evidence of pathogenicity. These data enabled the further
clinical characterization of KIS and a better understanding of the mechanistic complexity underlying this rare
genetic disorder. Currently, ACMGG/AMP guidelines
for variant classification have criteria for computational
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evidence (PP3) and for functional assays (PS3), but the
rigor, breadth, and complexity of the computational studies described here fail to be adequately captured by PP3.
When cell-based assays are not available for identified
variants, the appropriate utilization of computational
variant analysis for determining the pathogenicity of an
individual variant will become critical and is feasible as
herein demonstrated.
This study provides insight into the mechanistic complexity underlying this rare genetic disorder. It has demonstrated that KCNK9 variants can cause a variety of
effects on channel function ranging from upregulating
to downregulating current to differing effects on regulation by G
 αq and extracellular acidification. Yet, the dysregulation of TASK3, whether by an increase or decrease
of channel properties, is sufficient to cause a single clinical disorder, KIS, not separable according to the specific
functional impact. We may infer, then, that deviations
from normal current density in either direction ultimately lead to the same overall physiological effect and
clinical outcome. This has been shown in other genetic
conditions involving several different potassium channels, including K
 V1.2, KV2.1 KV7.2, and K
 ir1.2 channels
where, paradoxically, both loss and gain of function variants lead to hyperexcitability disorders such as epilepsy
[66]. Further, the most consistent observation (for about
70% of the variants) is a loss of regulation. So perhaps,
both during development and for functional responses in
maturity, the most important observation is not the current size, per se, but the appropriate channel response
to regulatory cues. In future work, further insight into
the functional consequences of the differing effects of
the KCNK9 variants that we have described could be
obtained from iPSC-derived neurons from patients harboring these variants. In addition to studying current
through the mutated channels in the neurons themselves,
this will allow us to measure the effects of the altered
channel function on the excitability and firing patterns of
these neurons and will provide a translational model for
therapeutic evaluation.
The observed variable effects on channel function
caused by the variants in KCNK9 have further ramifications on potential therapy for KIS. It was previously
hypothesized that channel-stimulatory drugs, such as
a subset of the nonsteroidal anti-inflammatory fenamic
acid class of drugs, may be useful in treating KIS as
flufenamic acid had been shown to partially rescue the
reduced current in Gly236Arg-mutated channels [14].
Graham et al. described the early results of treatment of
two individuals with KIS with mefenamic acid suggesting positive effects [8]. The data presented in this study
suggest that at a minimum these medications might only
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be affective for individuals with a subset of variants causing reduced current, similar to that of Gly236Arg. These
data may also suggest caution in treating an individual
with normal or increased channel current as we might
hypothesize exacerbated detrimental effects. However,
it may also indicate that this approach may be challenging to appropriately dose for maximal efficacy or
that without achieving proper channel regulation, little
benefit may be achieved. An alternative strategy could
be to increase expression of the normal paternal allele
as demonstrated by Cooper et al. [4]. It is possible that
paternal allele expression levels may be contributing to
the phenotypic variability observed, and if determined,
would support this as a possible treatment approach.
It is interesting to hypothesize that clinical benefit may
be achieved through treatment with medications such
as valproic acid, a known histone deacetylase (HDAC)
inhibitor, by promoting paternal allele expression. We
observed two patients in our study with seizures treated
with this medication showing good seizure control, but
further work is needed to determine if other KIS-associated symptoms also show improvement.

Conclusions
In summary, KIS is a neurodevelopmental disorder
caused by a spectrum of pathogenic variants on the
maternal allele of the paternally imprinted KCNK9 gene.
Variants disrupt TASK3 channel function by causing gain
or loss of current, or current regulation, demonstrating
the complexity underlying the mechanism of disease,
and likely requiring different methods of treatment.
These findings further characterize the clinical features
associated with this emerging disorder, demonstrate the
utility of computational modeling for understanding
variant impact on protein function, and bring caution
and suggestions to potential treatment strategies for
future studies.
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